Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16959
Abstract: Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line therapy (after ≥2 prior lines… read more here.
Keywords: line; third later; immune thrombocytopenia; line therapy ... See more keywords
Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): An open-label, single-arm, phase II study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e16297
Abstract: e16297 Background: Patients (pts) with mPDAC refractory to FOLFIRINOX and AG have limited therapeutic options. TAS-102 is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride,… read more here.
Keywords: 102 third; combined tas; third later; tas 102 ... See more keywords